Increased AAV Yield: From Screen to Scale Up to Cost Savings Using Viral Sensitizers (VSE™) Technology

Poster highlights how Virica’s Viral Sensitizer (VSE™) technology significantly enhances AAV production in ReiThera’s new proprietary ReiCell-AAV cell line. Using High-Throughput Virology (HTV™), Virica identified and validated top-performing VSEs that improved AAV yields over 4-fold in ReiThera’s ReiCell-AAV platform, tested at a 2L bioreactor scale. VSEs function by transiently suppressing innate cellular defenses and are rapidly metabolized, leaving no detectable residuals. Cost modeling shows that integrating VSEs can substantially reduce manufacturing costs, offering a scalable and cost-effective solution for cell and gene therapy developers.